Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been given an average rating of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $53.50.

Several equities research analysts have recently commented on SLN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Morgan Stanley raised their price target on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald started coverage on Silence Therapeutics in a report on Wednesday, June 24th. They set an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, June 17th.

Silence Therapeutics Stock Performance

Shares of NASDAQ:SLN opened at $11.22 on Friday. The firm has a market cap of $675.56 million, a P/E ratio of -8.77 and a beta of 1.45. Silence Therapeutics has a 52-week low of $4.19 and a 52-week high of $17.58. The business’s 50 day simple moving average is $12.76 and its two-hundred day simple moving average is $9.18.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. On average, equities analysts forecast that Silence Therapeutics will post -1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

Several large investors have recently bought and sold shares of SLN. ADAR1 Capital Management LLC boosted its holdings in Silence Therapeutics by 628.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after acquiring an additional 148,514 shares during the last quarter. 5AM Venture Management LLC bought a new position in shares of Silence Therapeutics during the second quarter valued at about $5,228,676. Seven Fleet Capital Management LP bought a new position in shares of Silence Therapeutics during the fourth quarter valued at about $897,000. Ishara Investments LP purchased a new position in Silence Therapeutics during the fourth quarter worth about $1,459,000. Finally, Squarepoint Ops LLC boosted its holdings in Silence Therapeutics by 29.6% during the second quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock worth $1,273,000 after purchasing an additional 26,449 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its proprietary mRNAi GOLD platform is designed to identify and silence specific messenger RNA targets, with the aim of producing durable effects from infrequent dosing.

The company’s pipeline includes zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease.